Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NHAPL enables homogeneous detection of RNA-associated glycan signals.

Biosensors & bioelectronics·2026
Same author

Can whole genome data analysis be used to personalize breast cancer care?

Translational cancer research·2026
Same author

Time-Restricted Eating and Metformin in Invasive Breast Cancer or DCIS: A Randomized, Phase IIb, Presurgical Trial. Preliminary Safety Analysis.

Cancer prevention research (Philadelphia, Pa.)·2025
Same author

Causal Relationships Between Plasma Metabolites and Risk of Dermatomyositis.

Clinical, cosmetic and investigational dermatology·2025
Same author

Metabolomics-based analysis of the correlation between lipid metabolites and thyroid carcinoma.

BMC biotechnology·2025
Same author

The burden of thyroid cancer and its association with national development levels in Asia: evidence from 47 countries (1990-2021).

Frontiers in oncology·2025

Related Experiment Video

Updated: Jul 7, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Celecoxib concentration predicts decrease in prostaglandin E2 concentrations in nipple aspirate fluid from high risk

Edward R Sauter1, Wenyi Qin, John E Hewett

  • 1Department of Surgery, University of Missouri, Columbia, MO, USA. sautere@health.missouri.edu

BMC Cancer
|February 13, 2008
PubMed
Summary

This study found that higher celecoxib plasma levels in high-risk women correlated with reduced prostaglandin E2 (PGE2) in breast tissue, suggesting a potential mechanism for celecoxib

Related Experiment Videos

Last Updated: Jul 7, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Epidemiologic studies link long-term, low-dose celecoxib use to reduced breast cancer risk.
  • Previous research showed celecoxib lowered prostaglandin E2 (PGE2) in postmenopausal women's plasma and nipple aspirate fluid (NAF).
  • Hypotheses proposed that circulating celecoxib levels influence PGE2 response and are affected by menopausal status.

Purpose of the Study:

  • To investigate the correlation between plasma celecoxib concentrations and changes in plasma/NAF PGE2 levels.
  • To determine if menopausal status impacts circulating celecoxib levels.

Main Methods:

  • 46 high-risk women received celecoxib (200 mg or 400 mg twice daily) for two weeks.
  • Matched NAF and plasma samples were collected pre- and post-treatment.
  • Celecoxib and PGE2 concentrations were analyzed.

Main Results:

  • In women on 400 mg celecoxib, higher plasma drug levels correlated with decreased NAF PGE2.
  • Postmenopausal women taking 400 mg celecoxib showed a significant reduction in NAF PGE2.
  • Trends suggested higher celecoxib levels in postmenopausal versus premenopausal women.

Conclusions:

  • Plasma celecoxib concentrations are associated with reduced PGE2 production in breast tissue of high-risk women.
  • Further research into synergistic strategies with celecoxib is warranted to optimize PGE2 downregulation and minimize drug dosage.